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F-box proteins are the substrate binding subunits of
SCF (Skp1-Cul1-F-box protein) ubiquitin ligase
complexes. Using affinity purifications and mass
spectrometry, we identified RRM2 (the ribonucleo-
tide reductase family member 2) as an interactor of
the F-box protein cyclin F. Ribonucleotide reductase
(RNR) catalyzes the conversion of ribonucleotides to
deoxyribonucleotides (dNTPs), which are necessary
for both replicative and repair DNA synthesis.
We found that, during G2, following CDK-mediated
phosphorylation of Thr33, RRM2 is degraded via
SCFcyclin F to maintain balanced dNTP pools and
genome stability. After DNA damage, cyclin F is
downregulated in an ATR-dependent manner to
allow accumulation of RRM2. Defective elimination
of cyclin F delays DNA repair and sensitizes cells to
DNA damage, a phenotype that is reverted by
expressing a nondegradable RRM2 mutant. In
summary, we have identified a biochemical pathway
that controls the abundance of dNTPs and ensures
efficient DNA repair in response to genotoxic stress.
INTRODUCTION
The ubiquitin-proteasome system allows the precise temporal
and spatial regulation of a large variety of regulatory proteins.
This tight control is accomplished through the specific, targeted
degradation of proteins via ubiquitin ligases. The Skp1-Cul1-
F-box protein (SCF) complexes are the canonical multisubunit
E3 ubiquitin ligases and assemble by using Cul1 as a core scaf-
fold (Cardozo and Pagano, 2004; Petroski and Deshaies, 2005).
The small RING protein Rbx1 and an ubiquitin conjugatingenzyme (UBC) are recruited via the C terminus of Cul1. The
Cul1 N terminus, instead, binds the bridging factor Skp1 and
a variable F-box protein, which determines substrate specificity.
Each F-box protein can target multiple substrates, allowing the
core SCF scaffold, by using different F-box proteins, to target
hundreds of substrates for degradation (Jin et al., 2004). Of
the 69 human F-box proteins, only a minority have established
functions (Skaar et al., 2009).
Cyclin F (also known as Fbxo1) is the founding member of the
F-box protein family and is essential for mouse development
(Bai et al., 1996; Tetzlaff et al., 2004). In addition to an F-box
domain, cyclin F contains a cyclin box domain, but, in contrast
to typical cyclins, it does not bind or activate any cyclin-depen-
dent kinases (CDKs) (Bai et al., 1996; D’Angiolella et al., 2010;
Fung et al., 2002; Tetzlaff et al., 2004). However, like other
cyclins, cyclin F protein levels oscillate during the cell division
cycle, peaking in G2.
Cyclin F localizes to both the centrosomes and the nucleus
(D’Angiolella et al., 2010). During G2, centrosomal cyclin F
targets CP110 for proteasome-mediated degradation to limit
centrosome duplication to once per cell cycle (D’Angiolella
et al., 2010). Additionally, cyclin F promotes the degradation of
NuSAP1, a protein involved in mitotic spindle organization (Ema-
nuele et al., 2011). The biological function of nuclear cyclin F
remains unknown.
Ribonucleotide reductase (RNR) is a well-studied enzyme
composed of two identical, large subunits (called RRM1,
RNR1, RR1, or R1) and two identical small subunits (called
RRM2, RNR2, RR2, or R2) (Nordlund and Reichard, 2006).
A functional catalytic site is constituted when two RRM2
(ribonucleotide reductase family member 2) subunits are bound
to two RRM1 (ribonucleotide reductase family member 1)
subunits. RNR catalyzes the conversion of ribonucleotides to
deoxyribonucleotides (dNTPs), which are used in the synthesis
of DNA during replication and repair (Nordlund and Reichard,
2006). Because of this fundamental function, RNR is amongCell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc. 1023
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Figure 1. Cyclin F and RRM2 Physically Interact and Colocalize to the Nucleus in G2
(A) RPE1-hTERT cells were synchronized in G0/G1 by 72 hr of serum starvation before release into fresh medium containing serum. Cells were collected at the
indicated time points after serum readdition (SR), lysed, and immunoblotted as indicated.
(B) HEK-293T cells were transfected with an empty vector (EV) or the indicated FLAG-tagged F-box protein constructs (FBPs). Whole-cell extracts were
immunoprecipitated (IP) with anti-FLAG resin, and immunoprecipitates were immunoblotted as indicated.
(C) HeLa cells were synchronized at G1/S by using a double-thymidine block before release into fresh medium. Cell lysates were generated at the indicated time
points, immunoprecipitated with an antibody to cyclin F, and immunoblotted as indicated. Ten percent of the material used for immunoprecipitation (input) is
shown on the right panels.
(D) U-2OS cells were synchronized at G1/S by using a double-thymidine block before release into fresh medium. Cells were fixed at 5 hr (S phase) and 9 hr
(G2 phase) after release from the block and stained with an antibody to cyclin F (green) or RRM2 (red). Where indicated, cells where pretreated for 2 hr with
Leptomycin B (LMB) before fixation. Confocal microscopy was used to visualize stained cells.
See also Table S1.the most well-conserved (from prokaryotes to eukaryotes) and
highly-regulated enzymes. Indeed, dNTP pool increases or
imbalances produce a hypermutator phenotype (Hu and Chang,
2007; Kunz et al., 1998), and decreased dNTP levels interfere
with proper DNA replication and repair (Nordlund and Reichard,
2006).
RNR activity needs to be coordinated with cell-cycle progres-
sion to preserve the fine balance between dNTP production and
DNA replication. RRM1 levels are constant throughout the cell
cycle and are always in excess of the level of RRM2, which
fluctuates during the cell cycle (Chabes and Thelander, 20001024 Cell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc.and Figure 1A). Therefore, the cell-cycle-dependent activity of
RNR is regulated by RRM2 levels. The G1/S induction of
RRM2 transcription is dependent on the transcription factor
E2F1 (Chabes et al., 2004; DeGregori et al., 1995), and, to
prevent RRM2 accumulation in G1, RRM2 levels are also kept
in check by the APC/CCdh1 ubiquitin ligase (Chabes et al.,
2003b). Notably, how RRM2 is degraded in the G2 phase of
the cell cycle remains unknown.
Although RNR is a cytoplasmic enzyme, in response to geno-
toxic stress, it translocates from the cytoplasm to the nucleus to
ensure the local availability of dNTPs at DNA damage sites for
DNA repair (Niida et al., 2010; Xu et al., 2008; Xue et al., 2003;
Zhang et al., 2009).
Here, we report the identification of RRM2 as a nuclear
substrate of the SCFcyclin F ubiquitin ligase and describe the
role of this interaction in ensuring genome stability and efficient
DNA repair synthesis.
RESULTS
During G2, Cyclin F Interacts with RRM2 in the Nucleus
To identify substrates of the SCFcyclin F ubiquitin ligase, FLAG-
HA-tagged cyclin F was transiently expressed in either HeLa
or HEK293T cells and immunopurified for analysis by Multidi-
mensional Protein Identification Technology (MudPIT) (D’Angio-
lella et al., 2010; Florens andWashburn, 2006). MudPIT revealed
the presence of peptides corresponding to Skp1 and Cul1, as
well as peptides derived from RRM2 (Table S1). Combining
both analyses, 23 total spectra, corresponding to five unique
RRM2 peptides, were identified. In two additional experiments,
we immunopurified cyclin F(1-270), a cyclin F mutant lacking
the cyclin box, and although Skp1 and Cul1 still coimmunopreci-
pitated with cyclin F(1-270), binding to RRM2 was not detected
(Table S1).
To investigate whether the binding between RRM2 and cyclin
F is specific, we screened a panel of human F-box proteins.
Fifteen FLAG-tagged F-box proteins were expressed in
HEK293T cells (with the proteasome inhibitor MG132 added
for 6 hr prior to harvesting) and immunoprecipitated to evaluate
their interaction with RRM2.We found that the only F-box protein
able to coimmunoprecipitate endogenous RRM2 was cyclin F
(Figure 1B). Through the use of synchronized HeLa cells
(monitored by immunoblotting for cell-cycle markers and flow
cytometry), the interaction between endogenous cyclin F and
endogenous RRM2 was observed exclusively in G2 and early
M (Figure 1C), when the levels of cyclin F increase and RRM2
levels are drastically reduced (Figures 1A and 1C).
Because cyclin F localizes to both the nucleus and centro-
somes (D’Angiolella et al., 2010) and RRM2 is largely cyto-
plasmic (Nordlund and Reichard, 2006), we asked where and
when the two proteins could colocalize. Synchronized U-2OS
cells were costained with antibodies to RRM2 and cyclin F.
As expected, cyclin F was nuclear, whereas RRM2was localized
to the cytoplasm in S phase cells and virtually absent in G2 cells
(Figure 1D). However, treatment of G2 cells with MG132,
a proteasome inhibitor, induced the accumulation of RRM2 in
both the nucleus and cytoplasm, as shown by confocal immuno-
fluorescence (Figure 1D). We also observed that, upon a brief
treatment of G2 cells with MG132 and the CRM1/exportin1
inhibitor Leptomycin B (LMB), RRM2 accumulated mostly in
the nucleus (Figure 1D, bottom panels). These results suggest
that during G2, RRM2 enters the nucleus to interact with and
be degraded via cyclin F, consistent with coimmunoprecipitation
experiments (Figure 1C).
We also mapped the RRM2 binding domain on cyclin F by
using a series of deletion mutants. A truncated version of cyclin
F that lacks the cyclin box domain and cyclin F mutated in its
hydrophobic patch domain [cyclin F(M309A)] failed to bind
RRM2 (Figures 2A and S1A–S1B, available online), similar toresults obtained with CP110 (D’Angiolella et al., 2010). However,
cyclin F(1-549), which retains the cyclin box domain but does not
localize to the nucleus (Figure S1C), was unable to bind RRM2
(Figures S1A–S1B), although this mutant still interacted with
CP110 (D’Angiolella et al., 2010), further confirming that the
cyclin F and RRM2 interact in the nucleus.
A CY Motif and Thr33 Are Required for RRM2 Binding
to Cyclin F
Subsequently, we mapped the cyclin F binding motif in RRM2.
A series of binding experiments, which used multiple RRM2
deletion mutants, narrowed the binding motif to a region of
RRM2 located between amino acids 40–65 (Figures S2A–S2B).
This region contains two putative CY motifs (RxL and RxI)
(Figure 2B), which are established cyclin binding domains
(Schulman et al., 1998). A mutant in the second motif
[RRM2(RxI/AxA)] failed to coimmunoprecipitate endogenous
cyclin F (Figure 2C), indicating that this CY motif, located at resi-
dues 49–51 of RRM2, mediates binding to cyclin F. In parallel,
we also performed Ala scanning mutagenesis of the region
encompassing amino acids 22–40 and found that, in addition
to the CY motif, Thr33 is also necessary for an efficient binding
to cyclin F (Figures 2B and 2C and S2C). Thr33 was previously
identified as a phosphorylated site in proteomic screens (Daub
et al., 2008; Mayya et al., 2009), therefore, we generated a phos-
pho-specific antibody against a peptide corresponding to amino
acids 35–50 of human RRM2 with Thr33 phosphorylated. This
antibody recognized wild-type RRM2 but not RRM2(T33A),
a mutant in which Thr33 was mutated to Ala (Figures 2C and
S2C). Using this antibody, we found that cyclin F coimmunopre-
cipitated the phosphorylated form of endogenous RRM2
(Figures 1B and 1C). Significantly, RRM2 was phosphorylated
on Thr33 predominantly in G2 and M (as indicated by the
increase in cyclin B levels and Histone H3 phosphorylation on
Ser10), when the levels of total RRM2 decrease and RRM2 inter-
acts with cyclin F (Figures 1A and 1C).
Thr33 in RRM2 Is Phosphorylated by CDKs to Promote
Binding to Cyclin F
The presence of a Pro at position 34 suggested that a Pro-
directed kinase phosphorylates Thr33, and the phosphorylation
of this residue in G2 and early M suggested that this kinase could
be a CDK. In support of this hypothesis, we found that three
different CDK inhibitors (NU6102, Roscovitine, and Alsterpaul-
lone) reduced RRM2 phosphorylation on Thr33, whereas
SB203580 (a p38 inhibitor), U0126 (a MEK inhibitor), DMAT (a
CKII inhibitor), and LY293646 (a DNA-PK inhibitor) had no effect
(Figure 2D). Moreover, both Cdk1-cyclin B and Cdk2-cyclin A,
but not Plk1 (another G2/M kinase), phosphorylated RRM2 on
Thr33 in vitro, as shown by immunoblotting with the phospho-
specific antibody (Figure 2E and data not shown). Importantly,
CDK-dependent phosphorylation of RRM2 was necessary for
its in vitro binding to cyclin F (Figure 2F).
Both Thr33 and the CY motif of RRM2 are highly conserved
across species (Figure S2D), and both are necessary, but not
sufficient, for a stable binding of RRM2 to cyclin F. RRM2(T33A),
which contains an intact CYmotif, did not efficiently bind cyclin F
in vivo or in vitro (Figures 2C, 2F, and S2C), and wild-type RRM2Cell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc. 1025
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Figure 2. Both a CY Motif and the Phosphorylation of Thr33 in RRM2 Are Required for RRM2 Binding to cyclin F
(A) HEK-293T cells were transfected with either an empty vector (EV), FLAG-tagged cyclin F, or the indicated FLAG-tagged cyclin F mutants. Whole-cell extracts
were immunoprecipitated (IP) with anti-FLAG resin, and immunocomplexes were immunoblotted as indicated.
(B) Schematic representation of RRM2mutants highlighting putative cyclin F bindingmotifs in RRM2. RRM2mutants that interacted with endogenous cyclin F are
designated with the symbol (+).
(C) HEK-293T cells were transfected with either an empty vector (EV), FLAG-tagged RRM2, or the indicated FLAG-tagged RRM2 mutants. Whole-cell extracts
were immunoprecipitated (IP) with anti-FLAG resin, and immunocomplexes were immunoblotted as indicated.
(D) HeLa cells were treated with the indicated kinase inhibitors. Cells were collected 4 hr later, lysed, and immunoblotted as indicated.
(E) In vitro transcribed/translated RRM2 was incubated at 30C with the indicated amounts of either Cdk1-cyclin B complex (upper panels) or Plk1 (bottom
panels). After 30 min, reactions were stopped, and samples were immunoblotted as indicated.
(F) In vitro-transcribed/translated RRM2 or RRM2(T33A) were incubated at 30C in the presence or absence of Cdk1-cyclin B. After 30 min, in vitro transcribed/
translated HA-cyclin F was added to the reaction and incubated for an additional 30 min. Cyclin F was then immunoprecipitated with an anti-HA antibody, and
immunocomplexes were immunoblotted as indicated.
(G) HeLa cell extracts were incubated with beads coupled to the following peptides: RRM2 (26–39) (SLVDKENTPPALSG), phospho-RRM2 (26–39) (SLVDKENTp-
PPALSG), RRM2 (30–60) (KENTPPALSGTRVLASKTARRIFQEPTEPK), phospho-RRM2 (30–60) (KENTp-PPALSGTRVLASKTARRIFQEPTEPK), RRM2 (40–60)
(TRVLASKTARRIFQEPTEPK), p27 (180–198) (NAGSVEQTPKKPGLRRRQT), or phospho-p27 (180–198) (NAGSVEQTp-PKKPGLRRRQT). Beads were extensively
washed, and bound proteins were immunoblotted as indicated.
See also Figures S1 and S2.was unable to bind cyclin F in vitro without prior phosphorylation
by aCDK (Figure 2F). However, RRM2(RxI/AxA), inwhichThr33 is
intact, was unable to bind cyclin F, even though phosphorylation1026 Cell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc.of Thr33 was unaffected (Figure 2C), and a peptide correspond-
ing to amino acids 26–39 of RRM2 (i.e., a peptide that does not
contain the CY motif) was unable to bind cyclin F irrespective
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Figure 3. RRM2 Is Targeted for Ubiquitylation and Degradation
by SCFcyclin F
(A) HeLa cells were transfected with siRNAs to either a nonrelevant mRNA
(LacZ) or cyclin F mRNA. Cells were synchronized at G1/S by a double-
thymidine block and collected at the indicated time points after release from
the block. Cell lysates were immunoblotted as indicated.
(B) Cyclin F/ and parental Cyclin FFlox/ MEFs were lysed and immuno-
blotted as indicated.
(C) 35[S]-in vitro-translated RRM2 or RRM2(T33A) were incubated at 30Cwith
Cdk1-cyclin B and then, for the indicated times, with a ubiquitylation mix
containing purified, recombinant SCFcyclin F. Reactions were analyzed by
autoradiography. The bracket indicates a ladder of bands corresponding to
polyubiquitylated RRM2.
See also Figure S3.of the Thr33 phosphorylation state (Figure 2G). Notably, whereas
neither domain was sufficient for cyclin F binding, several lines of
evidence indicate that phosphorylation of RRM2 on Thr33 does
not provide an interface for cyclin F binding and instead exposes
the CY motif at residues 49–51 for cyclin F recognition: (1)
a peptide corresponding to amino acids 30–60 of RRM2 was
able to bind cyclin F irrespective of the Thr33 phosphorylation
state (Figure 2G); (2) a peptide corresponding to amino acids
40–60 of RRM2 was able to efficiently bind cyclin F (Figure 2G);
and (3) RRM2(40–389), a mutant in which the first 39 amino acids
were deleted, interactedwith cyclin F in vivo as efficiently aswild-
type RRM2 (Figure S2B). Thus, when the first 30–40 amino acidsof cyclin F are deleted (and the CY motif at 49–51 is presumably
exposed), Thr33 becomes dispensable.
RRM2 Is Targeted for Degradation by SCFCyclin F
We noted that, compared to wild-type cyclin F, the cyclin
F(LP/AA) mutant (in which the first two amino acids of the
F-box domain were mutated to alanine) bound less Skp1 and
Cul1 (as expected) and more RRM2 (Figure 2A). This result sug-
gested that RRM2 is targeted for proteolysis by cyclin F because
this mutant is unable to form an active SCF ubiquitin ligase and
can sequester RRM2. To test whether cyclin F regulates the
degradation of RRM2, we used three established siRNA oligos
(D’Angiolella et al., 2010) to reduce the expression of cyclin F
in synchronizedHeLa cells. We also silenced Cyclin F expression
in synchronized U-2OS and RPE1-hTERT cells by using themost
effective of the three oligos. In all cases, depletion of cyclin F
inhibited the G2-specific degradation of RRM2 (Figures 3A and
S3A and data not shown). Significantly, compared to controls,
the amount of RRM2 phosphorylated on Thr33 drastically
increased, confirming that it is the phosphorylated form of
RRM2 that is targeted by SCFcyclin F. Upon cyclin F depletion
in G2 cells, RRM2 half-life increased (Figure S3B) and RRM2
accumulated mostly in the cytoplasm because of active
nucleus-cytoplasm shuttling, as indicated by its nuclear
accumulation following LMB treatment (Figure S3C). Moreover,
in agreement with the siRNA results, we observed that Cyclin
F/ mouse embryonic fibroblasts (MEFs) (Tetzlaff et al.,
2004) displayed RRM2 accumulation compared to parental
Cyclin FFlox/ MEFs (Figure 3B). Finally, purified wild-type cyclin
F, but not cyclin F(LP/AA), promoted the in vitro ubiquitylation of
RRM2, but not RRM2(T33A) (Figures 3C and S3D and S3E), sup-
porting the hypothesis that cyclin F directly controls the
ubiquitin-mediated degradation of RRM2.
Cyclin F-Mediated Degradation of RRM2 Prevents
Genome Instability
Together, the results shown in Figures 1, 2, 3, S1, S2, and S3
demonstrate that cyclin F mediates the nuclear degradation of
RRM2 in G2. To investigate the biological significance of this
event, we analyzed synchronized HeLa, U-2OS, and RPE1-hTert
cells expressing either HA-tagged wild-type RRM2, HA-tagged
RRM2(RxI/AxA), or HA-tagged RRM2(T33A). In G2 and M,
wild-type RRM2 was degraded, whereas RRM2(RxI/AxA) and
RRM2(T33A) were not (Figures 4A and 4BB and S4A–S4C), in
agreement with their inability to efficiently bind cyclin F (Fig-
ure 2C). Importantly, the expression of stable RRM2 mutants
induced an increase in the cellular concentration of dATP and
dGTP, but not dCTP and dTTP (Figures 4C and S4D), creating
an imbalance in dNTP pools. This result is consistent with
a reduction of purine dNTPs, but not pyrimidine dNTPs, in cells
treated with either hydroxyurea, an RNR inhibitor, or an siRNA
to RRM2 (Ha˚kansson et al., 2006; Lin et al., 2007; Lin et al.,
2004), and it is likely due to a more efficient nucleotide salvage
pathway for pyrimidine deoxyribonucleosides than purine deox-
yribonucleosides (Reichard, 1988).
We also synchronized in prometapahse RPE1-hTert cells
infected with either an empty retrovirus or a retrovirus expres-
sing HA-tagged wild-type RRM2, HA-tagged RRM2(T33A), orCell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc. 1027
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Figure 4. Expression of Stable RRM2 Mutants Induces an Increase in the Concentration of dATP and dGTP
(A) HeLa cells infected with either a retrovirus expressing HA-tagged RRM2 or HA-tagged RRM2(T33A) were synchronized by using a double-thymidine block.
Samples were collected at the indicated times after release, lysed, and immunoblotted as indicated.
(B) HeLa cells infected with either a retrovirus expressing HA-tagged RRM2 or HA-tagged RRM2(RxI/AxA) were analyzed as in (A).
(C) RPE1-hTert cells infected with either a retrovirus expressing HA-tagged RRM2, HA-tagged RRM2(T33A), or HA-tagged RRM2(RxI/AxA) were enriched for the
G2 and M populations and lysed to assess the concentration of dNTPs. Each data point represents the mean ± standard deviation (SD) of three separate
experiments.
(D) RPE1-hTert cells infected with either an empty virus (EV) or a retrovirus expressing HA-tagged wild-type (WT) RRM2, HA-tagged RRM2(T33A), or HA-tagged
RRM2(RxI/AxA) were incubated for 16 hr with nocodazole and subjected to a mitotic shake-off to isolate round, prometaphase cells, which were subsequently
released into fresh medium. Samples were collected at the indicated times after release from the block, lysed, and immunoblotted as indicated.
(E) RPE1-hTert cells were treated as in (D). Three hours after release from the prometaphase arrest, cells were lysed to quantify dNTP concentrations. Each data
point represents the mean ± SD of three separate experiments.
See also Figure S4.HA-tagged RRM2(RxI/AxA) (Figure 4D). Cells were released from
the block, and, 3 hr after, the majority of cells were in G1, as indi-
cated by the disappearance of Histone H3 phosphorylated on
Ser10. In all cases, when cells reached the next G1, the levels
of both endogenous and exogenous RRM2 decreased (Fig-
ure 4D), likely due to APC/CCdh1 (Chabes et al., 2003b), which
does not require either T33 or the RxI motif to interact with
RRM2 (Figures 2C and 2G). Yet, in G1, levels of RRM2(T33A)
and RRM2(RxI/AxA) remained higher than endogenous RRM2
(Figure 4D). Consistent with this observation, the concentrations
of purine dNTPs were higher in G1 cells expressing stable RRM2
mutants compared to wild-type cells (Figure 4E).
Failures in the control of dNTP levels have been shown to lead
to genome instability (Chabes et al., 2003a; Hu and Chang, 2007;1028 Cell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc.Ke et al., 2005; Kunz, 1988; Kunz et al., 1994;Meuth, 1989; Phear
and Meuth, 1989; Xu et al., 2008). To test whether expression of
the RRM2mutants inducedmutations, wemeasured the sponta-
neous mutation frequency of the gene encoding hypoxanthine
phosphoribosyl transferase (HPRT). Because of the presence
of HPRT, cells are sensitive to 6-thioguanine (6-TG), thus, the
occurrence of resistant clones represents spontaneous muta-
tions at the HPRT locus (Dare` et al., 1995). Upon 6-TG selection,
and after adjusting for plating efficiency, we observed that,
compared to cells transfected with an empty vector or express-
ing wild-type RRM2, cells expressing stable RRM2 mutants
developed approximately 20 and 40 times more resistant colo-
nies, respectively (Figure 5A), corresponding to 20- and 40-fold
increases in mutation frequency.
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Figure 5. Cyclin F-Mediated Degradation of RRM2 Prevents
Genome Instability
(A) The frequency of mutations at the HPRT locus was determined in U-2OS
cells infected with a retrovirus expressing either RRM2 or the indicated
HA-tagged RRM2mutants. Each data point represents the mean ± SD of three
separate experiments.
(B) The frequency of mutations at the HPRT locus was determined in
U-2OS cells transfected with siRNAs to either a nonrelevant mRNA (LacZ) or
cyclin F mRNA. Each data point represents the mean ± SD of three separate
experiments.These experiments show that the regulation of RRM2 degra-
dation via cyclin F is required to maintain dNTP pool balance
and prevent genome instability. Accordingly, cyclin F silencing
mimicked the phenotypes observed following expression of
stable RRM2 mutants (i.e., unbalanced dNTP pools and
increased rate of mutation) (Figures 5B and S4E).
Finally, we generated and sequenced HPRT cDNAs from 21
individual 6-TG resistant clones expressing stable RRM2
mutants. Mutations, including deletions, transversions, transi-
tions, and insertions were found in all 21 HPRT coding
sequences in these clones. Interestingly, 15 of the 21 clones
analyzed showed skipping of exon 8. This deletion has been
reported to depend on mutations in the pyrimidine rich tract of
intron 7 (Andersson et al., 1992), which is consistent with the
increased levels of purines detected in cells expressing stable
RRM2 or depleted of cyclin F (Figures 4C, 4E, and S4D).
Upon Genotoxic Stress, Cyclin F Is Downregulated
and RRM2 Accumulates in a ATR-Dependent Manner
In response to DNA damage, RRM2 is recruited to the nucleus to
guarantee local availability of dNTPs for efficient DNA repair
synthesis (Chabes and Thelander, 2000; Lin et al., 2007; Niida
et al., 2010; Zhang et al., 2009). We found that, in any cell line
tested, and in response to a number of DNA damaging agents
(e.g., doxorubicin, CPT, UV-C, MMS, NCZ, or g-irradiation), the
levels of cyclin F drop, with coincident accumulation of RRM2
(Figures 6A and 6B, and data not shown). These changes were
not due to changes in cell-cycle distribution (Figure S5A) and,
in fact, similar protein oscillations were observed in cells
synchronized in G2 (Figures S5B and S5C). These events
appeared to be dependent on ATM and/or ATR, as caffeine
inhibited both cyclin F degradation and RRM2 accumulation
(Figure 6A). We then observed that cyclin F was still degradedand RRM2 was still upregulated in immortalized fibroblasts
obtained from Ataxia Telangiectasia (AT) patients (Figure 6C),
which carry a mutated ATM gene. In contrast, when ATR was
ablated from HCT116 ATRFlox/ cells (Cortez et al., 2001; Martin
et al., 2011); this response was deficient (Figure 6D). Finally, we
excluded that this function is mediated by CHK1, a kinase
activated by ATR because silencing CHK1 expression did
not affect cyclin F downregulation (Figure S5D). Thus, cyclin F
downregulation is mediated by ATR, but not ATM, in a Chk1-
independent manner.
The downregulation of cyclin F protein in response to geno-
toxic stress was at least partially due to degradation. In fact,
whereas the levels and stability of cyclin F mRNA did not change
significantly after DNA damage, treatment of cells with the
proteasome inhibitor MG132 prevented the disappearance of
cyclin F (Figures S6A and S6B). When expressed at near physi-
ologic levels, exogenous cyclin F was downregulated similar
to the endogenous protein (Figure S6C). Analysis of the stability
of different truncation mutants suggested that cyclin F downre-
gulation upon DNA damage depends on amotif located between
amino acids 407 and 660 (data not shown) and a cyclin F
fragment encompassing amino acids 407–660was able to trans-
fer DNA damage-dependent instability to GFP (Figure S6D). This
domain contains three SerGln (526, 534, 595) and four ThrGln
sites (427, 467, 472, 543), which are potential sites of phosphor-
ylation by ATR, and although two of these seven sites are
conserved in mammals, none are conserved throughout verte-
brates. Mutation of these seven residues to Ala did not abrogate
the sensitivity of cyclin F to genotoxic stress (Figure S6C), sug-
gesting the effect of ATR on cyclin F stability is indirect.
Cyclin F Downregulation Is Required for Efficient DNA
Repair
In agreement with previous reports (Niida et al., 2010; Xu et al.,
2008; Xue et al., 2003; Zhang et al., 2009), we found that in
response to genotoxic stress, RRM2 accumulates in the
nucleus, as detected by immunofluorescence staining of
U-2OS cells (Figure S7A) or immunoblotting of the chromatin
fractions from either HeLa or RPE1-hTERT cells (Figures 7A
and S7B). Thus, we hypothesized that cyclin F downregulation
is a prerequisite for the accumulation of nuclear RRM2. To test
this hypothesis, we either infected HeLa cells with doxycy-
cline-repressible cyclin F constructs [wild-type cyclin F, cyclin
F(M309A)])(Figure 7A) or transiently expressed wild-type cyclin
F in RPE1-hTERT cells (Figure S7B), and subjected them to
various forms of DNA damage. In contrast to control cells,
RRM2 failed to accumulate in cells expressing wild-type cyclin
F, whereas cells expressing the inactive cyclin F(M309A) mutant
retained the ability to accumulate nuclear RRM2.
We then performed alkaline comet assays to monitor DNA
repair and found that cells expressing wild-type cyclin F, but
not cyclin F(M309A), displayed a reduced ability to repair
damaged DNA (Figure 7B). Accordingly, compared to control
cells, many more cells died (as judged by clonogenic survival)
after UV treatment when expression of wild-type cyclin F,
but not cyclin F(M309A) or cyclin F(LP/AA), was induced in
HeLa cells by removing doxycycline (Figures 7C and S7C).
Significantly, expression of a stable RRM2 mutant [eitherCell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc. 1029
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Figure 6. Upon Genotoxic Stress, Cyclin F Is
Downregualated and RRM2 Accumulates in a
ATR-Dependent Manner
(A) HCT116, U-2OS, and HeLa cells were treated with
doxorubicin (DRB) for the indicated times. After DRB
treatment, cells were collected, lysed, and immunoblotted
as indicated.
(B) HeLa cells were treated with the indicated DNA
damaging agents: or (camptothecin), MMS (methyl meth-
anesulfonate), UV (8 J/m2). Cells were collected at the
indicated times after treatment, lysed, and immunoblotted
as indicated.
(C) Normal Human Fibroblasts immortalized with hTert
(NHFs) and GM0252A-hTert fibroblasts from an ataxia-
teleangectasia patient (AT cells) were treated with DRB.
Cells were collected at the indicated times after treatment,
lysed, and immunoblotted as indicated.
(D) HCT116 ATR Flox/ cells were incubated with 4-OHT
(4-hydroxytamoxifen) for 24 hr (to induce ATR ablation)
and then with doxorubicin (DRB). Cells were collected
at the indicated times after DRB treatment, lysed, and
immunoblotted as indicated.
See also Figures S5 and S6.RRM2(RxI/AxA) or RRM2(T33A)], but not wild-type RRM2, re-
verted the UV sensitivity induced by the expression of cyclin F
(Figure 7D and data not shown), indicating that the downregula-
tion of cyclin F after genotoxic stress is required to allow RRM2
accumulation within the nucleus and, consequently, efficient
DNA repair.
DISCUSSION
Here we report that RRM2 is targeted for degradation by
SCFcyclin F during theG2 phase of the cell cycle (seemodel in Fig-
ure 7E). Failure to degrade RRM2 in G2 promotes imbalances in
dNTP pools (both at G2/M and during the next G1) and an1030 Cell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc.increased frequency of mutations (Figures 4, 5,
and S4). Imbalances in dNTP pools result in
increased base misincorporation during DNA
synthesis and decreased proofreading due to
enhanced polymerization rates (Mathews,
2006). Abnormal dNTP levels negatively affect
the fidelity of DNA replication, producing an
increase in gene mutation rate and genome
instability. In agreement with these data, (1)
elevated or imbalanced pools of dNTPspromote
transformation and induce an increase in the rate
of spontaneous mutations in cell systems
(Chabes et al., 2003a; Hu and Chang, 2007; Ke
et al., 2005;Kunz, 1988;Kunzet al., 1994;Meuth,
1989; Phear and Meuth, 1989), (2) overexpres-
sion of RRM2 induces the development of lung
cancer in mice (Xu et al., 2008), and (3) elevated
levels of RRM2 correlate with poor prognoses
for cancer patients (Ferrandina et al., 2010;
Gradeet al., 2011; Joneset al., 2011;Kretschmer
et al., 2011; Morikawa et al., 2010a; Morikawa
et al., 2010b; Satow et al., 2010).Oncogenic stress produces dNTP deficiencies and a conse-
quent DNA replication stress typical of early oncogenic events
(Bester et al., 2011). In contrast, expression of an RRM2 stable
mutant increases the dNTP pool, but it does not induce DNA
replication stress, as indicated by the lack of Chk1 phosphoryla-
tion or induction of 53BP1 bodies in G1 nuclei (Figure S4A and
data not shown) (G1 nuclear 53BP1 bodies mark DNA lesions
induced by replication stress [Lukas et al., 2011]). These findings
suggest that mammalian cells may not have a checkpoint that
senses dNTP pool increases, highlighting the risk of elevated
RRM2 levels for the pathogenesis of cancer.
An interesting aspect of RRM2 degradation via SCFcyclin F is
its regulation by CDKs. In fact, although cyclin F utilizes its
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Figure 7. Cyclin F Downregulation Is Required for Efficient DNA Repair
(A) HeLa cells infected with a pLVX Tet-Off lentivirus and either pLVX-Tight-puro Cherry-cyclin F or pLVX-Tight-puro Cherry-cyclin F(M309A) lentiviruses were
treated with or without doxycyclin (DOXY) for 48 hr. Next, cells were treated with UV (4 J/m2) for the indicated times. After treatment, cell pellets were divided into
chromatin and soluble fractions and immunoblotted as indicated.
(B) HeLa cells treated as in (A) were subjected to alkaline comet assays. Each data point represents themean ±SD of three separate experiments in which at least
100 cells per sample were counted.
(C) HeLa cells were treated as in (A), except that the indicated doses of UVwere used. A colony formation assaywas performed 10 days after treatment. Each data
point represents the mean ± SD of three separate experiments.
(D) HeLa cells preinfected with either pBabe HA-tagged RRM2 or pBabe HA-tagged RRM2(RxI/AxA) were infected as described in (A), and exposed to the
indicated UV doses. A colony formation assay was performed 10 days after treatment. Each data point represents the mean ± SD of three separate experiments.
(E) A model of the regulation of DNA replication and repair by the cyclin F-RRM2 axis. During G2, after the last majority of DNA replication has occurred, cyclin F
accumulates, thereby promoting RRM2 degradation in collaboration with a G2 CDK. DNA damage induces a ATR-dependent downregulation of cyclin F to allow
accumulation of RRM2 for efficient DNA repair.
See also Figure S7.hydrophobic patch to recognize the CY motif in RRM2 (similar to
other cyclin-substrate pairs), it does so only after RRM2 is phos-
phorylated by CDKs on Thr33, an event that appears to expose
the CYmotif (Figure 2 and S2B). Thus, the mode of RRM2 recog-
nition by cyclin F is an exception to the rule that cyclin-substrateinteractions do not require posttranslational modifications, high-
lighting the unique nature of RRM2 regulation. Interestingly,
RRM2 is also phosphorylated by CDKs on Ser20 (Chan et al.,
1993; Chan et al., 1999). However, in contrast to Thr33 phos-
phorylation, this modification occurs early in S phase, does notCell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc. 1031
affect RRM2 stability, and its function remains unknown (Chabes
and Thelander, 2000).
After genotoxic stress, the levels of cyclin F in both p53-
positive and p53-negative cells rapidly drop, allowing the recruit-
ment of RRM2 to chromatin for efficient DNA repair synthesis
(Figures 6, 7E, S5, and S6). This function is consistent with
reports indicating a role for RNR in guaranteeing availability of
dNTPs at the sites of DNA damage (Lin et al., 2007; Niida
et al., 2010; Zhang et al., 2009). The timing of RRM2 accumula-
tion following DNA damage parallels the timing of DNA repair
(Figures 6, 7A, and 7B). The rapid accumulation of RRM2 protein
requires cyclin F downregulation, which occurs in an ATR-
dependent, but Chk1- and transcription-independent, manner
(Figures 6 and S5C and S5D). However, if DNA damage persists,
RRM2 upregulation also relies on Chk1- and E2F1-dependent
transcription (Zhang et al., 2009). Moreover, upon persistent
genotoxic stress, a different RNR subunit, called RRM2B or
p53R2 (which normally substitutes for RRM2 to form an active
RNR complex necessary for the synthesis of mitochondrial
DNA [Bourdon et al., 2007; Wang et al., 2011]), accumulates
much later (48–72 hr later) after DNA damage in a p53-depen-
dent manner (Ha˚kansson et al., 2006; Tanaka et al., 2000).
We have previously shown that cyclin F controls centrosome
duplication and prevents chromosome instability by promoting
the degradation of CP110 (D’Angiolella et al., 2010). Our current
study reveals that cyclin F controls the cellular dNTP pools and
prevents genome instability by promoting RRM2 degradation.
Thus, cyclin F is a hub that coordinates and synchronizes centro-
some duplication with DNA replication to ensure proper cell
division. Interestingly, hydroxyurea (HU) inhibits RNR and
induces centrosome duplication in certain cell types (Balczon
et al., 1995; Meraldi et al., 1999). The fact that cyclin F, but not
CP110, is degraded after HU treatment (D’Angiolella et al.,
2010) may explain why HU (by blocking RNR) induces dissocia-
tion of centrosome duplication from DNA replication.
In addition to the fundamental implications for our under-
standing of cell physiology, our studies have clinical relevance
because they provide insight into the response to genotoxic
stress caused by HU, gemcitabine, fludarabine phosphate, and
cladribine, RNR-inhibiting drugs that are used in the treatment
of various cancers, including leukemia, melanoma, metastatic
ovarian cancer, nonsmall cell lung cancer, and pancreatic
cancer (Shao et al., 2006). Moreover, because the failure to
downregulate cyclin F in response to DNA damage blocks
nuclear accumulation of RRM2 and induces cell death, we
propose that the inhibition of cyclin F degradation may be useful
for enhancing the chemosensitivity of cancer cells to DNA
damage-based therapies.EXPERIMENTAL PROCEDURES
Biochemical Methods
Extract preparation, immunoprecipitation, and immunoblotting have been
previously described (Bassermann et al., 2008; Guardavaccaro et al., 2008).
Subcellular fractionation was performed as described (Ballabeni et al.,
2004). Briefly, Soluble fraction was extracted by using CSK buffer (0.5% Triton
X-100, 10 mM Pipes [pH 6.8], 100 mM NaCl, 1.5 mMMgCl2, 300 mM sucrose,
1 mM aprotinin, 1 mM leupeptin, and 1 mM PMSF). Cells lysates were centri-
fuged at 1,700 rcf for 4 min. After centrifugation, cell pellets were washed and1032 Cell 149, 1023–1034, May 25, 2012 ª2012 Elsevier Inc.insoluble proteins were extracted by using CSK buffer containing 250 mM
NaCl and Turbo Nuclease (Accelagen).
Purification and MudPIT Analysis
HEK293T cells were transfected with constructs encoding either FLAG-HA-
tagged cyclin F or FLAG-HA-tagged cyclin F(1-270). Cell lysis, immunopurifi-
cation, and MS/MS analysis have been previously described (D’Angiolella
et al., 2010).
Immunofluorescence Microscopy
Cells were fixed with PFA 4% for 10 min, permeabilized with PBS containing
1% Triton X-100 for 10 min and blocked for 1 hr in PBS containing 0.1% Triton
X-100 3% BSA prior to incubation with primary antibodies. (Please note that
PFA does not allow detection of centrosomal cyclin F.) Secondary antibodies
were from donkey and conjugated with Alexa Fluor fluorochromes (Invitrogen).
DAPI was used to stain DNA. Slides were mounted with Prolong-Gold (Invitro-
gen). Confocal microscopy was performed by using a Zeiss LSM 510, equip-
ped with Zeiss LSM 510 software.
Establishment of Tet-Off HeLa Cells Expressing Cherry Cyclin F
and pBABE HA-Tagged RRM2
pLVX-Tight-puro Cherry-cyclin F, pLVX-Tight-puro Cherry-cyclin(FM309A),
pLVX Tet-Off lentiviruses were produced according to the manufacturer
instruction (Clontech). HeLa cells (preinfected or not with pBABE vectors
expressing wild-type or mutant RRM2) were infected with lentiviruses; positive
clones were selected by using puromycin (1 mg/ml) and G418 (800 mg/ml), and
grown in the presence of Doxycycline (2 mg/ml). Doxycycline removal induced
Cherry-cyclin F expression.
Gene Silencing by Small Interfering RNA
The sequences of the oligonucleotides numbers 1, 2, and 3, corresponding to
the cyclin F mRNA, were CCAGUUGUGUGCUGCAUUA, UAGCCUACCU
CUACAAUGA, and GCACCCGGUUUAUCAGUAA, respectively. A dsRNA
oligo to LacZ mRNA (CGUACGCGGAAUACUUCGA) served as a negative
control (Duan et al., 2012).
Determination of dNTP Pool in Whole-Cell Extracts
U-2OS and RPE1-hTERT cells (53 106) were washed twice with cold PBS and
extracted by using 1 ml of ice-cold 60% methanol for 1 hr at 20C, followed
by centrifugation for 15 min at 14,000 3 g. The supernatant was dried under
vacuum; the pellet was dissolved in 200 ml of sterile water and stored
at 20C. Determination of the dNTP pool size was based on DNA poly-
merase-catalyzed incorporation of radioactive dNTP into the synthetic oligo-
nucleotide template as described (Sherman and Fyfe, 1989).
Determination of Mutation Rates
For stable transfection U-2OS cells were infected with pBABE retroviruses ex-
pressing HA-tagged RRM2, HA-tagged RRM2(T33A), and HA-tagged
RRM2(RxI/AxA). After infection, cells were selected by using puromycin for
2 days. Mutation frequencies were determined by HPRT mutation as
described (Xu et al., 2008). 6-TG resistant clones were subcultured in
24-well format. When individual clones reached confluence, RNA was
extracted and cDNA was synthesized with Fast Lane cDNA synthesis kit
(QIAGEN), according to manufacturer’s instruction. The HPRT open reading
frame was PCR amplified by using the following primers: 50-CTGAGCAGT
CAGCCCGCG-30 and 50-GAGAATTTTTTCATTTACAAGTTAAACAACAATCC
GCC-30. HPRT mutations were identified vis direct sequencing of PCR
products by using the following primers: 50-CGCCGGCCGGCT-30 and
50-GGCTCATAGTGCAAATAAACA-30.
Comet Assay
Alkaline comet assays were performed by using a Trevigen’s Comet Assay
kit (4250-050-k) according to the manufacturer’s instructions. DNA was
stained with SYBR Green, and slides were photographed by using a Zeiss
Axiovert 200 M microscope, equipped with a cooled Retiga 2000R CCD
(QImaging). Tail moments were analyzed as reported previously (Park et al.,
2006) by using the Tritek Comet Score Freeware.
Clonogenic Assay
Tet-off HeLa cells expressing Cherry-cyclin F or Cherry-cyclin F(M309A) were
irradiated with varying doses of UV-C in the presence or absence of doxycy-
cline (2 mg/ml) and then washed with PBS. Ten days after an additional incuba-
tion, surviving colonies were counted and their relative numbers were
expressed as percentages of the untreated cells as described (Franken
et al., 2006).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at doi:10.1016/
j.cell.2012.03.043.
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